Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with acute and chronic pain. Founded in 2006, Heron has made significant strides in the industry, particularly with its proprietary formulations that enhance patient outcomes while minimising opioid use.
The company’s flagship products, including the non-opioid analgesic Zynrelef and the anti-emetic agent Cinvanti, stand out for their unique delivery mechanisms and efficacy. Heron Therapeutics has established a strong market position, recognised for its commitment to improving patient care through science-driven solutions. With a robust pipeline and a dedication to addressing unmet medical needs, Heron continues to shape the future of pain management and supportive care in the healthcare landscape.
-18 vs industry average
Heron Therapeutics, Inc.’s score of 20 is lower than 25% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Heron Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Heron Therapeutics, Inc. yet.
Heron Therapeutics, Inc.'s reported carbon emissions
Heron Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Heron Therapeutics may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time.
As the company does not inherit emissions data from a parent organisation, it operates independently regarding its climate impact reporting. In the context of the pharmaceutical industry, where many companies are increasingly adopting science-based targets and sustainability initiatives, Heron Therapeutics may need to consider developing a comprehensive climate strategy to align with industry standards and stakeholder expectations.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Heron Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Heron Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Heron Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project